Altoida Raises $6.3M Series A to Predict Alzheimer's Disease Risk Using Artificial Intelligence, Machine Learning and Augmented Reality New digital biomarkers company detects Alzheimer's Disease (AD) 6-10 years prior to onset of Mild Cognitive Impairment (MCI) symptoms due to AD - with up to 94% accuracy HOUSTON, May 30, 2019-- Altoida Inc. today announced a $6.3 million round of venture capital financing to bring its FDA-cleared and CE Mark-approved medical device and brain health data platform to patients, physicians and researchers around the globe.